Brace Pharma Capital participated in a round that took the total raised by the rare genetic disease drug developer to more than $85m.

AvroBio, a US-based developer of treatments for rare diseases, has closed a $60m series B round that included Brace Pharma Capital, the investment firm formed by pharmaceutical company EMS.

Cormorant Asset Management and Surveyor Capital co-led the round, which also featured Aisling Capital, Eventide Asset Management, Morningside Venture Capital, Atlas Venture, SV Health Investors and Clarus Ventures.

AvroBio is working on gene therapies for rare diseases and will put the series B funding into advancing its lead product candidate, AVR-RD-01,…